Document type
ArticleVersion
Published versionPublication date
Publication license
Please use this identifier to cite or link to this item: https://hdl.handle.net/2445/205748
Developing New Strategies for Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Journal Title
Authors
Director/Tutor
Journal ISSN
Volume Title
Related resource
Abstract
Diffuse large B-cell lymphoma (DLBCL) is an aggressive and biologically heterogeneous disease. Approximately 40% of patients with DLBCL will experience disease relapse or will be refractory to first-line chemo immunotherapy. In recent years, there have been several new therapeutic agents approved for the treatment of relapsed/refractory (R/R) DLBCL. These agents include anti-CD19 chimeric antigen receptor T-cell (CAR T-cell) and monoclonal antibody therapies such as polatuzumab and tafasitamab. Nevertheless, despite the high efficacy of all these new therapies, there are still patients who do not respond or relapse, representing an unmet clinical need. This review describes new promising therapies that are in clinical development to treat R/R DLBCL.
Subject
Citation
Citation
GONZÁLEZ BARCA, Eva. Developing New Strategies for Relapsed/Refractory Diffuse Large B-Cell Lymphoma. Journal of Clinical Medicine. 2023. Vol. 12, num. 23, pags. 7376. ISSN 2077-0383. [consulted: 13 of August of 2026]. Available at: https://hdl.handle.net/2445/205748